Valorizing Agro‐Food Waste for Nutraceutical Development: Sustainable Approaches for Managing Metabolic Dysfunction‐Associated Steatotic Liver Disease and Related Co‐Morbidities DOI Creative Commons
Laura Comi, Claudia Giglione, Fationa Tolaj

и другие.

Food Frontiers, Год журнала: 2024, Номер unknown

Опубликована: Дек. 25, 2024

ABSTRACT This comprehensive investigation delves into the interconnectedness of different features cardiometabolic syndrome, such as metabolic dysfunction‐associated steatotic liver disease (MASLD), atherosclerotic cardiovascular (ASCVD), and gut dysbiosis, highlighting crucial role nutraceuticals in their management prevention. Given significant overlap pathophysiology these conditions, treatment with nutraceuticals, especially those derived from agro‐food waste, offers a promising, sustainable, innovative approach to healthcare. The 2030 Agenda for Sustainable Development One Health concept are key frameworks selecting most interesting supply chain production ensuring environmental sustainability, agricultural practices. In this review, therapeutic potential kiwifruit apples has been explored, detailing how bioactive compounds, like polyphenols, fiber, pectin, kaempferol, phloretin, phlorizin, may contribute MASLD, ASCVD, dysbiosis. Various extraction methods active ingredients, including chemical, water, enzyme extractions, analyzed respective benefits drawbacks. By integrating scientific research, sustainable practices, methods, we can develop effective strategies combat pervasive health issues. holistic not only enhances individual outcomes but also supports broader societal goals, promoting healthier future all.

Язык: Английский

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review DOI Creative Commons

Haixiang Zheng,

Leonardo A. Sechi, Eliano Pio Navarese

и другие.

Cardiovascular Diabetology, Год журнала: 2024, Номер 23(1)

Опубликована: Сен. 28, 2024

Язык: Английский

Процитировано

21
Metabolic syndrome traits differentially and cumulatively influence micro‐ and macrovascular disease risk in patients with MASLD DOI Creative Commons
Alex E. Henney, David R. Riley, Theresa Hydes

и другие.

Liver International, Год журнала: 2024, Номер 44(11), С. 3031 - 3049

Опубликована: Сен. 2, 2024

Abstract Introduction The cumulative impact of metabolic syndrome (MetS) components on micro‐ and macrovascular disease in dysfunction‐associated steatotic liver (MASLD) is unclear. We aimed to determine whether the number MetS increases risk patients with MASLD. Methods performed a retrospective cohort study electronic medical records using TriNetX network, global federated database. exposure arm was hepatic steatosis (defined via International Classification Diseases, 10th Revision coding, or modified index), ≥1 (obesity/central adiposity, insulin resistance, hypertension, dyslipidaemia), compared reference adults without any steatosis. Our propensity score matched (1:1) for confounders 5 years follow‐up. Primary outcomes included microvascular (peripheral neuropathy, retinopathy, nephropathy) (cardiovascular events, cerebrovascular accidents, peripheral vascular disease) disease. Secondary analyses assessed additional these outcomes, as well sex. Results MASLD, defined by resistance ( n = 15 937), carried highest (HR 13.93 (95% CI 8.55–22.68)), whilst hypertension 53 028), (7.23 (6.45–8.13)). MASLD all greatest both (31.20 (28.88–33.70) 462 789)) (8.04 (7.33–8.82) 336 010)) Conclusion demonstrate differential effect multiple overall risk. most pronounced women. Aggressive factor management critical prevention complications.

Язык: Английский

Процитировано

6
Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation DOI Creative Commons
Federico Carbone, Jean‐Pierre Després, John P. A. Ioannidis

и другие.

European Journal of Clinical Investigation, Год журнала: 2025, Номер unknown

Опубликована: Май 15, 2025

Abstract Background Most forms of obesity are associated with chronic diseases that remain a global public health challenge. Aims Despite significant advancements in understanding its pathophysiology, effective management is hindered by the persistence knowledge gaps epidemiology, phenotypic heterogeneity and policy implementation. Materials Methods This consensus statement European Society for Clinical Investigation identifies eight critical areas requiring urgent attention. Key include insufficient long‐term data on trends, inadequacy body mass index (BMI) as sole diagnostic measure, recognition diversity obesity‐related cardiometabolic risks. Moreover, socio‐economic drivers transition across phenotypes poorly understood. Results The syndemic nature obesity, exacerbated globalization environmental changes, necessitates holistic approach integrating frameworks community‐level interventions. advocates leveraging emerging technologies, such artificial intelligence, to refine predictive models address variability. It underscores importance collaborative efforts among scientists, policymakers, stakeholders create tailored interventions enduring policies. Discussion highlights need harmonizing anthropometric biochemical markers, fostering inclusive narratives combating stigma obesity. By addressing these gaps, this initiative aims advance research, improve prevention strategies optimize care delivery people living Conclusion effort marks decisive step towards mitigating epidemic profound impact systems. Ultimately, should be considered being largely consequence model not compatible optimal human health.

Язык: Английский

Процитировано

0
Research Progress of Different Fat Pools and Atherosclerosis DOI

真 张

Advances in Clinical Medicine, Год журнала: 2025, Номер 15(05), С. 1628 - 1634

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Effect of Oral Microbiota Composition on Metabolic Dysfunction-Associated Steatotic Liver Disease in the General Population DOI Open Access
Satoshi Sato, Chikara Iino,

K. Furusawa

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(6), С. 2013 - 2013

Опубликована: Март 16, 2025

Background/Objective: This study investigated the relationship between composition of oral microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD) in general population. Methods: In total, 712 participants a health check-up project were divided into four patterns by principal component analysis cluster analysis; they included Neisseria, Streptococcus, Fusobacterium, Veillonella groups. The Neisseria group had largest number patients was used as reference to compare incidence MASLD cardiometabolic criteria with other Results: multivariate analysis, risk factor for independent compared group. correlation bacterial species MASLD-related items showed that negatively correlated controlled attenuation parameters, body mass index, waist circumference, hemoglobin A1c, alanine aminotransferase, fatty index. positive blood pressure, triglycerides, aspartate gamma-glutamyl transpeptidase, negative high-density lipoprotein cholesterol. contrast, Streptococcus Fusobacterium groups not clearly associated MASLD. Conclusions: Maintaining hygiene preventing periodontitis may contribute extending healthy lifespan.

Язык: Английский

Процитировано

0
Lean MASLD and Cardiovascular Disease: A Review DOI

Nachum Lebovics,

Gabriel Heering,

William H. Frishman

и другие.

Cardiology in Review, Год журнала: 2025, Номер unknown

Опубликована: Март 21, 2025

Metabolic-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty disease, is prevalent worldwide and highly associated with cardiovascular (CVD). Lean MASLD defined by hepatic steatosis cardiometabolic risk factors in individuals a body mass index below 25 Western populations or 23 Asian populations. Paradoxically, some studies indicate that lean an elevated of (CV) CV mortality compared nonlean MASLD. patients exhibit distinctive metabolic, genetic, microbiome profiles contributing to increased visceral adiposity, sarcopenia, fibrosis, systemic inflammation, endothelial dysfunction. This review examines the epidemiology, pathophysiology, outcomes MASLD, addressing discrepancies literature. Furthermore, it highlights current clinical guidelines, emphasizes lifestyle modifications, discusses emerging pharmacotherapies potential treatment options.

Язык: Английский

Процитировано

0
Liver steatosis is positively associated with plasminogen activator inhibitor-1 in apparently healthy individuals with overweight and obesity: A FibroScan-Based Cross-Sectional study DOI Creative Commons
Giuseppe Lisco, Davide Guido,

Nicole Cerabino

и другие.

Journal of Translational Medicine, Год журнала: 2025, Номер 23(1)

Опубликована: Апрель 29, 2025

Язык: Английский

Процитировано

0
From MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status DOI Creative Commons
Andrea Boccatonda, Damiano D’Ardes, Veronica Moronti

и другие.

Medicina, Год журнала: 2024, Номер 60(11), С. 1781 - 1781

Опубликована: Окт. 31, 2024

Peripheral artery disease (PAD) is still the least studied and evaluated form in clinical practice among atherosclerotic pathologies, despite increased mortality comorbidities related to it. The relationship between steatotic liver an risk of cardiovascular has been extensively documented.

Язык: Английский

Процитировано

2
Exploring the Th2 Response in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Potential Modulator of the Renin-Angiotensin System (RAS) Pathway in Hypertension Development DOI Creative Commons
Lucia A. Méndez‐García, Galileo Escobedo,

Itzel Baltazar-Pérez

и другие.

Life, Год журнала: 2024, Номер 14(9), С. 1080 - 1080

Опубликована: Авг. 29, 2024

Non-alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction-associated steatotic (MASLD), is alarmingly increasing alongside the cases of obesity worldwide. MASLD an underestimated abnormality closely linked with a higher risk developing systemic arterial hypertension (SAH). However, underlying mechanism association between and SAH remains unknown. Inflammation may link these two entities by regulating renin-angiotensin system (RAS). For this reason, in study, we evaluated hepatic expression cytokine profile critical molecules RAS pathway patients morbid MASLD, both SAH. We found statistically significant correlation ACE levels cytokines IL-4, IL-10, IL-13 Th2 response. Furthermore, according multiple linear regression analysis, IL-4 were best predictors levels. Moreover, observed increased obesity, compared those without These results allow us propose, for first time, that response, through RAS, could play role individuals obesity.

Язык: Английский

Процитировано

1
Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease DOI Creative Commons

Tatjána Ábel,

Béla Benczúr, Éva Csajbókné Csobod

и другие.

Frontiers in Medicine, Год журнала: 2024, Номер 11

Опубликована: Сен. 23, 2024

Previously published studies have shown that women with type 2 diabetes a higher risk of atherosclerotic cardiovascular disease than men diabetes. The exact reason for this is not yet known. association between metabolic dysfunction-associated steatotic liver and appears to be bidirectional, meaning the onset one may increase progression other. Dyslipidemia common in both diseases. Our aim was therefore investigate whether there sex difference pathogenesis management dyslipidemia patients dysfunction. While majority date found no statin treatment, some reduced effectiveness compared men. Statin treatment under-prescribed diabetics disease. No differences were ezetimibe treatment. However, best our knowledge, such study fibrate Conflicting results on efficacy newer cholesterol-lowering PCSK9 inhibitors been reported Results from two real-world suggest up-titration dose improves women. Bempedoic acid has effective safe more lipid lowering men, based phase 3 date. Further research needed clarify plays role ASCVD

Язык: Английский

Процитировано

1